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Dear Editor, 
 
this study analyses APC gene (Adenomatous polyposis coli) in a 29-year-old 
female patient with oligoastrocytoma. Oligoastrocytoma sample was tested for gene 
instability by PCR/loss of heterozygosity using RFLP method. Allelic loss of the APC 
gene was found in our patient. We wanted to inform you on this interesting finding 
which may contribute to better understanding of oligoastrocytoma genetic profile.  
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Introduction 
 
Our interest in elucidating the role of tumor suppressor gene—adenomatous 
polyposis coli (APC) stemmed principally from the findings that wild-type APC 
protein is highly expressed in the central nervous system, and upon the finding that 
APC protein is critically involved in particular syndromes, among which the brain 
tumours play a significant role [1]. 
Besides the structural role of the APC gene in adherens junctions [2], the 
protein product of the APC gene plays a signaling role as a negative regulator of the 
wnt pathway [3]. Components of the wnt signaling pathway, are also implicated in 
tumor genesis. Mutations in the adenomatous polyposis coli gene are responsible for 
familial adenomatous polyposis and the majority of sporadic colorectal cancers. 
However, a large variety of other tumors exhibit mutations of this suppressor gene 
[4]. 
The mutations of APC gene are also found in some syndromes, like the 
Tourcot's syndrome, which among other include the development of brain tumors 
such as medulloblastomas and gliomas [1, 5]. 
Oligoastrocytoma is a tumor which is composed of a mixture of two distinct 
neoplastic cell types morphologically resembling the tumor cells in diffuse 
astrocytoma (WHO grade II) and oligodendroglioma [6]. Oligoastrocytoma 
corresponds hystologically to WHO grade II [7]. 
The molecular genetic alterations underlying the oncogenesis and progression 
of oligoastrocytomas appear to be more heterogeneous than those associated with 
ordinary astrocytomas and oligodendrogliomas. 
Patient and Methods 
29 years old female patient was admitted to the Department of Neurosurgery, 
University Hospital “Sestre Milosrdnice”, Zagreb, Croatia with manifesting 
symptoms of raised intracranial pressure including severe headache and nausea 
caused by a brain tumor.  
Using the magnetic resonance imaging (MRI) we found a tumor lesion in the 
right parietal region, with the surrounding zone of perifocal oedema. During the 
operative procedure the tumor was maximally reduced using a microneurosurgical 
technique.  
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The collected tumor tissue was frozen in liquid nitrogen and transported to the 
laboratory, where it was immediately frozen at -75°C. The peripheral blood sample 
was processed immediately.  
The local Ethical Committee approved our study and the patient gave her informed 
consent. 
DNA extraction. Tumor sample for DNA isolation was the parts of obvious tumor 
mass (evaluated by neurosurgeon and based on macroscopic appearance and tissue 
color, density, and consistency on gross section). The sample was also evaluated for 
the percentage of tumor cells by pathologist and consisted of more than 80% of tumor 
cells.  
 Approximately 0.5 g of tumor tissue was homogenized with 1 ml extraction 
buffer (10 mM Tris HCl, pH 8.0; 0.1 M EDTA, pH 8.0; 0.5% sodium dodecyl sulfate) 
and incubated with proteinase K (100 µg/ml; Sigma, USA; overnight at 37°C). Phenol 
chloroform extraction and ethanol precipitation followed.  
 Blood sample was used to extract lymphocyte DNA. Five ml of blood was 
lysed with 7 ml distilled water and centrifuged (15 min/5000 g). The pellet was then 
processed as for DNA extraction from the tissue samples. 
Polymerase chain reaction. The optimal reaction mixture (25 µl) for APC's exon 11 
amplification was: 20 pmol of each primer (5'-GGACTACAGGCCATTGCAGAA-3' 
and 5'-GGCTACATCTCCAAAAGTCAA-3'), 200 µM of each dNTP, 200-400 ng 
template DNA, 1 µl (0.5 U) of Taq polymerase, 1 mM MgCl2, 5 µl 10 X reaction 
buffer II (500 mM KCl, 100 mM Tris-HCl, pH 8.3). Polymerase chain reaction (PCR) 
conditions were: initial denaturation, 4 min/95°C; denaturation, 1 min/94°C; 
annealing, 2 min/58°C; extension, 1.5 min/72°C; 35 cycles. The PCR products were 
analyzed on 2% agarose gels.  
Restriction fragment length polymorphism. Loss of heterozygosity (LOH) of the 
APC gene was detected on the basis of restriction fragment length polymorphism 
(RFLP) of the PCR products. A Rsa I polymorphic site in exon 11 was investigated. 
PCR amplification of exon 11 generated a 133- bp fragment that is cleaved to 85- and 
48- bp fragments by Rsa I restriction if the polymorphic site is present, and remains 
uncleaved if the site is absent. PCR aliquots (10–15 µl) were digested with 6 U Rsa I 
(Gibco, USA; 12 h at 37°C) and were electrophoresed on 15% polyacrylamide gels 
and on Spreadex EL 300 gels (Elchrom scientific, Switzerland), stained with 
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SyberGold (Molecular Probes, Netherlands). LOH/Rsa I was demonstrated only in 
informative (heterozygous) persons when the tumor DNA showed loss of either the 
single uncut band (133 bp) or of the two cut bands (85+48 bp) compared to 
autologous blood DNA.  
 
Results and discussion 
The histopathological diagnosis of oligoastrocytoma was based on recognition 
of two different glial components both of which are unequivocally neoplastic which is 
shown in figure 1.  
Immunohistological analysis revealed strong reactivity to glial fibrillary acidic 
protein (GFAP) in astocytic areas of differentiation while zones with oligodendroglial 
differentiation contain predominantly GFAP negative cells.   
The analysis of Rsa I polymorphic site in APC’s exon 11 of our proband's 
blood sample showed that the patient was heterozygous for this polymorphism. 
Moreover, the oligoastrocytoma sample demonstrated LOH when compared to the 
patient's constitutive DNA as shown on figure 2. We performed analysis on Spreadex 
gel and  confirmed it on 13% polyacrylamide gel stained with silver. This finding led 
us to conclude that our sample comprised gross deletion of the APC gene. 
The mechanisms of brain tumor initiation and progression have not yet been 
completely investigated and elucidated. As with other tumors, the formation of brain 
tumors is the result of multiple consecutive genetic changes that represent a critical 
factor in tumor evolution  [8]. No consistent genetic abnormalities have been detected 
that would indicate the genetic profile of oligoastrocytomas [9, 10]. Our result offers 
APC tumor suppressor gene as a potential candidate involved in development of 
oligoastrocytoma. We consider our finding a small but relevant contribution to 
understanding pathophysiological mechanisms of brain tumor formation. 
Further investigation regarding this gene on a bigger sample should be 
performed in future to confirm our suggestion.  
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Legends to the figures 
Figure 1. Oligoastrocytoma showing the two distinct cell population separated in 
different areas; oligodendroglial (left) and astrocytic (right) differentiation, (HE, x 
400). 
 
 
Figure 2. Loss of heterozygosity of gene APC in a 29-year-old-patient with 
oligoastrocytoma. Exon 11/RsaI/RFLP. Lane 1 - standard DNA/50 bp ladder; lane 2, 
–LOH, cut allele is missing; lane 3 – corresponding informative blood sample, both 
alleles, cut and uncut, are visible. 
 
